A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations

被引：17

作者：

Sa, Huanlan ^{[1
]}

Shi, Yan ^{[2
]}

Ding, Chunxia ^{[1
]}

Ma, Kewei ^{[1
]}

机构：

[1] First Hosp Jilin Univ, Ctr Canc, 1 Xinmin St, Changchun 130021, Jilin, Peoples R China

[2] Binzhou Med Univ Hosp, Dept Ultrasonog, Binzhou 256603, Shandong, Peoples R China

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023年 / 149卷 / 10期

关键词：

Epidermal growth factor receptor mutations; Exon; 20; insertions; Furmonertinib; Non-small cell lung cancer; Tyrosine kinase inhibitor; MOLECULAR HETEROGENEITY; CLINICAL ACTIVITY; NSCLC; OSIMERTINIB; DOCETAXEL; TRIAL;

D O I：

10.1007/s00432-023-04726-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Furmonertinib is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). A phase Ib study (FAVOUR, NCT04858958) initially demonstrated the efficacy of furmonertinib in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins). This study aimed to investigate the real-world efficacy and safety of furmonertinib in patients with advanced NSCLC with EGFR ex20ins. Methods We retrospectively examined patients with advanced NSCLC with EGFR ex20ins having complete follow-up data, who were treated with furmonertinib from April 14, 2021, to March 15, 2022, at our institution and multiple hospitals in China. Objective response rate (ORR), disease control rate (DCR), 6-month progression-free survival (PFS) rates and treatment related adverse events (TRAEs) were assessed. Results This study included 53 patients with advanced NSCLC with EGFR ex20ins. A767_V769dup (28.3%) and S768_ D770dup ( 11.3%) are the major variants. The ORR and DCR were 37.7% (20/53) and 92.5% (49/53), respectively. The 6-month PFS rate was 69.4% (95% CI 53.7-85.1%). The ORR of patients in the 240 mg once-daily dosage group was higher (42.9%) than that of patients in the 80 mg once-daily (25.0%) and 160 mg once-daily (39.5%) groups, but with no statistically significant difference (P = 0.816). The ORR of furmonertinib is not dependent on insertion location (P = 0.893). Patients with central nervous system (CNS) metastases at baseline responded similarly to those without CNS metastases (ORR: 33.3% vs. 40.6%, P = 0.773). The most common AEs were diarrhea (26.4%) and rash (26.4%). No grade >= 3 TRAEs were observed. No statistically significant difference was observed in the incidence of TRAEs between dosage groups (P = 0.271). Conclusions Furmonertinib has shown encouraging antitumor activity and CNS activity in patients with advanced NSCLC with EGFR ex20ins. Moreover, furmonertinib had a good safety profile and no dose-dependent toxicity.

引用

页码：7729 / 7742

页数：14

共 41 条

[21] Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [J].

Shepherd, FA ;

Dancey, J ;

Ramlau, R ;

Mattson, K ;

Gralla, R ;

O'Rourke, M ;

Levitan, N ;

Gressot, L ;

Vincent, M ;

Burkes, R ;

Coughlin, S ;

Kim, Y ;

Berille, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) :2095-2103

[22] Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study [J].

Shi, Yuankai ;

Chen, Gongyan ;

Wang, Xiang ;

Liu, Yunpeng ;

Wu, Lin ;

Hao, Yanrong ;

Liu, Chunling ;

Zhu, Shuyang ;

Zhang, Xiaodong ;

Li, Yuping ;

Liu, Jiwei ;

Cao, Lejie ;

Cheng, Ying ;

Zhao, Hui ;

Zhang, Shucai ;

Zang, Aimin ;

Cui, Jiuwei ;

Feng, Jian ;

Yang, Nong ;

Liu, Fei ;

Jiang, Yong ;

Gu, Chuan .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (11) :1297-1305

[23] Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study [J].

Shi, Yuankai ;

Chen, Gongyan ;

Wang, Xiang ;

Liu, Yunpeng ;

Wu, Lin ;

Hao, Yanrong ;

Liu, Chunling ;

Zhu, Shuyang ;

Zhang, Xiaodong ;

Li, Yuping ;

Liu, Jiwei ;

Cao, Lejie ;

Cheng, Ying ;

Zhao, Hui ;

Zhang, Shucai ;

Zang, Aimin ;

Cui, Jiuwei ;

Feng, Jian ;

Yang, Nong ;

Liu, Fei ;

Jiang, Yong ;

Gu, Chuan .

LANCET RESPIRATORY MEDICINE, 2022, 10 (11) :1019-1028

[24] Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation [J].

Shi, Yuankai ;

Zhang, Shucai ;

Hu, Xingsheng ;

Feng, Jifeng ;

Ma, Zhiyong ;

Zhou, Jianying ;

Yang, Nong ;

Wu, Lin ;

Liao, Wangjun ;

Zhong, Dafang ;

Han, Xiaohong ;

Wang, Ziping ;

Zhang, Xiaodong ;

Qin, Shukui ;

Ying, Kejing ;

Feng, Jian ;

Fang, Jian ;

Liu, Li ;

Jiang, Yong .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (06) :1015-1026

[25] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J].

Soria, J. -C. ;

Ohe, Y. ;

Vansteenkiste, J. ;

Reungwetwattana, T. ;

Chewaskulyong, B. ;

Lee, K. H. ;

Dechaphunkul, A. ;

Imamura, F. ;

Nogami, N. ;

Kurata, T. ;

Okamoto, I. ;

Zhou, C. ;

Cho, B. C. ;

Cheng, Y. ;

Cho, E. K. ;

Voon, P. J. ;

Planchard, D. ;

Su, W. -C. ;

Gray, J. E. ;

Lee, S. -M. ;

Hodge, R. ;

Marotti, M. ;

Rukazenkov, Y. ;

Ramalingam, S. S. ;

Boyer, Michael ;

Lee, Chee ;

Hughes, Brett ;

O'Byrne, Kenneth ;

Briggs, Peter ;

Milward, Michael ;

John, Thomas ;

Demedts, Ingel ;

Vansteenkiste, Johan ;

Bustin, Frederique ;

Barrios, Carlos Henrique ;

Timcheva, Constanta ;

Butts, Charles ;

Goss, Glenwood ;

Juergens, Rosalyn ;

Leighl, Natasha ;

Cheng, Susanna ;

Burkes, Ronald ;

Zhou, Caicun ;

Zhang, Helong ;

Shu, Yongqian ;

Cheng, Ying ;

Zhou, Qing ;

Li, Wei ;

Feng, Guosheng ;

He, Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) :113-125

[26] A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer [J].

Tu, Hai-Yan ;

Ke, E-E ;

Yang, Jin-Ji ;

Sun, Yue-Li ;

Yan, Hong-Hong ;

Zheng, Ming-Ying ;

Bai, Xiao-Yan ;

Wang, Zhen ;

Su, Jian ;

Chen, Zhi-Hong ;

Zhang, Xu-Chao ;

Dong, Zhong-Yi ;

Wu, Si-Pei ;

Jiang, Ben-Yuan ;

Chen, Hua-Jun ;

Wang, Bin-Chao ;

Xu, Chong-Rui ;

Zhou, Qing ;

Mei, Ping ;

Luo, Dong-Lan ;

Zhong, Wen-zhao ;

Yang, Xue-Ning ;

Wu, Yi-Long .

LUNG CANCER, 2017, 114 :96-102

[27] Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer [J].

van Veggel, B. ;

Santos, J. F. Vilacha Madeira R. ;

Hashemi, S. M. S. ;

Paats, M. S. ;

Monkhorst, K. ;

Heideman, D. A. M. ;

Groves, M. ;

Radonic, T. ;

Smit, E. F. ;

Schuuring, E. ;

van der Wekken, A. J. ;

de Langen, A. J. .

LUNG CANCER, 2020, 141 :9-13

[28] Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study [J].

Wang, M. ;

Yang, J. C-H. ;

Mitchell, P. ;

Fang, J. ;

Nian, W. ;

Chiu, C. H. ;

Zhou, J. ;

Zhao, Y. ;

Su, W-C. ;

Camidge, D. R. ;

Yang, T-Y. ;

Zhu, V. ;

Millward, M. ;

Fan, Y. ;

Cheng, Y. ;

Jiang, L. ;

Zheng, L. ;

Jaenne, P. A. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S1003-S1004

[29] Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations [J].

Wang, Mengzhao ;

Yang, James Chih-Hsin ;

Mitchell, Paul L. ;

Fang, Jian ;

Camidge, D. Ross ;

Nian, Weiqi ;

Chiu, Chao-Hua ;

Zhou, Jianying ;

Zhao, Yanqiu ;

Su, Wu-Chou ;

Yang, Tsung-Ying ;

Zhu, Viola W. ;

Millward, Michael ;

Fan, Yun ;

Huang, Wen-Tsung ;

Cheng, Ying ;

Jiang, Liyan ;

Brungs, Daniel ;

Bazhenova, Lyudmila ;

Lee, Chee Khoon ;

Gao, Bo ;

Xu, Yan ;

Hsu, Wei-Hsun ;

Zheng, Li ;

Janne, Pasi A. .

CANCER DISCOVERY, 2022, 12 (07) :1676-1689

[30] A Phase II Study of Osimertinib for Radiotherapy- Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L) [J].

Yamaguchi, Hiroyuki ;

Wakuda, Kazushige ;

Fukuda, Minoru ;

Kenmotsu, Hirotsugu ;

Mukae, Hiroshi ;

Ito, Kentaro ;

Chibana, Kenji ;

Inoue, Kohji ;

Miura, Satoru ;

Tanaka, Kentaro ;

Ebi, Noriyuki ;

Suetsugu, Takayuki ;

Harada, Taishi ;

Kirita, Keisuke ;

Yokoyama, Toshihide ;

Nakatani, Yuki ;

Yoshimura, Kenichi ;

Nakagawa, Kazuhiko ;

Yamamoto, Nobuyuki ;

Sugio, Kenji .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) :2121-2132

← 1 2 3 4 5 →